Drug Resistance in Glioblastoma: The Two Faces of Oxidative Stress
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Glioblastomas (GBM) are the most common primary brain tumor with a median survival of 15 months. A population of cells with stem cell properties (glioblastoma stem cells, GSCs) drives the initiation and progression of GBM and is localized in specialized microenvironments which support their behavior. GBM are characterized as extremely resistant to therapy, resulting in tumor recurrence. Reactive oxygen species (ROS) control the cellular stability by influencing different signaling pathways. Normally, redox systems prevent cell oxidative damage; however, in gliomagenesis, the cellular redox mechanisms are highly impaired. Herein we review the dual nature of the redox status in drug resistance. ROS generation in tumor cells affects the cell cycle and is involved in tumor progression and drug resistance in GBM. However, excess ROS production has been found to induce cell death programs such as apoptosis and autophagy. Since GBM cells have a high metabolic rate and produce high levels of ROS, metabolic adaptation in these cells plays an essential role in resistance to oxidative stress-induced cell death. Finally, the microenvironment with the stromal components participates in the enhancement of the oxidative stress to promote tumor progression and drug resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
How mitochondria produce reactive oxygen species
Murphy, M. P. (2009) · Biochemical Journal · doi:10.1042/bj20081386 · Cited by 8,207
Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
Trachootham, D., Alexandre, J., & Huang, P. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2803 · Cited by 5,452 · cited 1×
“An elevated activity of the latter enzymes and an increase in the level of reduced glutathione (GSH) are associated with the acquisition of resistance (Trachootham et al., 2009; Ortega et al., 2011).”
BackgroundThe senescence-associated secretory phenotype: the dark side of tumor suppression
Coppé, J.-P., Desprez, P.-Y., Krtolica, A., & Campisi, J. (2010) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-121808-102144 · Cited by 5,206
Role of nrf2 in oxidative stress and toxicity
Ma, Q. (2013) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011112-140320 · Cited by 4,903 · cited 1×
“The shift between activation and inactivation of Nrf-2 protects GBM cells from the deleterious effects of ROS in cells produced by therapy, thereby preventing apoptosis and sustaining cell survival (Ma, 2013).”
BackgroundOrimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Cell Survival Responses to Environmental Stresses Via the Keap1-Nrf2-ARE Pathway
Kensler, T. W., Wakabayashi, N., & Biswal, S. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141046 · Cited by 3,630 · cited 2×
“2013) and is an essential antioxidant transcription factor regulator in cells against xenobiotics capable of triggering DNA damage and initiating carcinogenesis (Kensler et al., 2007).”
BackgroundCrosstalk of reactive oxygen species and NF-κB signaling
Morgan, M. J., & Liu, Z.-G. (2011) · Cell Research · doi:10.1038/cr.2010.178 · Cited by 3,505
Greaves, M., & Maley, C. C. (2012) · Nature · doi:10.1038/nature10762 · Cited by 3,162 · cited 1×
“Indeed, interactions between the tumor cells, ECM, soluble factors and blood vessels generate an intricate diverse environment that is in continual transformation supporting and maintaining tumorigenesis (Greaves and Maley, 2012).”
BackgroundAssociation of reactive oxygen species levels and radioresistance in cancer stem cells
Diehn, M., Cho, R. W., Lobo, N. A., Kalisky, T., Dorie, M. J., Kulp, A. N., Qian, D., Lam, J. S., Ailles, L. E., Wong, M., et al. (2009) · Nature · doi:10.1038/nature07733 · Cited by 2,555
Mammalian thioredoxin is a direct inhibitor of apoptosis signal‐regulating kinase (ASK) 1
Saitoh, M., Nishitoh, H., Fujii, M., Takeda, K., Tobiume, K., Sawada, Y., Kawabata, M., Miyazono, K., & Ichijo, H. (1998) · The EMBO Journal · doi:10.1093/emboj/17.9.2596 · Cited by 2,377
A restricted cell population propagates glioblastoma growth after chemotherapy
Chen, J., Li, Y., Yu, T.-S., McKay, R. M., Burns, D. K., Kernie, S. G., & Parada, L. F. (2012) · Nature · doi:10.1038/nature11287 · Cited by 2,354
Cyclooxygenase regulates angiogenesis induced by colon cancer cells
Tsujii, M., Kawano, S., Tsuji, S., Sawaoka, H., Hori, M., & DuBois, R. N. (1998) · Cell · doi:10.1016/s0092-8674(00)81433-6 · Cited by 2,272 · cited 1×
“The latter plays a key role in inflammation (Smith et al., 1996) and COX-2 by stimulating the release of pro-angiogenic prostaglandins (Tsujii et al., 1998), acting on tumorigenesis and tumor growth.”
BackgroundHIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption
Papandreou, I., Cairns, R. A., Fontana, L., Lim, A. L., & Denko, N. C. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.012 · Cited by 2,267
Hypoxia in cancer: significance and impact on clinical outcome
Vaupel, P., & Mayer, A. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9055-1 · Cited by 2,240
Bissell, M. J., & Radisky, D. (2001) · Nature Reviews Cancer · doi:10.1038/35094059 · Cited by 2,180
Reactive oxygen species are essential for autophagy and specifically regulate the activity of Atg4
Scherz‐Shouval, R., Shvets, E., Fass, E., Shorer, H., Gil, L., & Elazar, Z. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601623 · Cited by 2,101
Beyond oxidative stress: an immunologist's guide to reactive oxygen species
Nathan, C., & Cunningham-Bussel, A. (2013) · Nature Reviews Immunology · doi:10.1038/nri3423 · Cited by 1,619
Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells
Li, Z., Bao, S., Wu, Q., Wang, H., Eyler, C., Sathornsumetee, S., Shi, Q., Cao, Y., Lathia, J., McLendon, R. E., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.018 · Cited by 1,354
Role of Glutathione in Cancer Progression and Chemoresistance
Traverso, N., Ricciarelli, R., Nitti, M., Marengo, B., Furfaro, A. L., Pronzato, M. A., Marinari, U. M., & Domenicotti, C. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/972913 · Cited by 1,208 · cited 2×
“In the brain, GSH and GSH-related enzymes, glutathione peroxidase (Gpx1), are essential for the elimination of ROS and detoxification (Traverso et al., 2013).”
BackgroundNRF2 and cancer: the good, the bad and the importance of context
Sporn, M. B., & Liby, K. T. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3278 · Cited by 1,067 · cited 1×
“The translocation of Nrf-2 to the nucleus caused by OS has been shown to activate the glutamate cysteine ligase modifier subunit, glutathione S-transferase π, GSH availability and use, glutathione reductase, and glutathione peroxidase (Sporn and Liby, 2012; Rocha et al., 2016).”
BackgroundCycling hypoxia and free radicals regulate angiogenesis and radiotherapy response
Dewhirst, M. W., Cao, Y., & Moeller, B. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2397 · Cited by 1,022
Metabolic requirements for the maintenance of self-renewing stem cells
Ito, K., & Suda, T. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3772 · Cited by 1,014
Tebay, L. E., Robertson, H., Durant, S. T., Vitale, S. R., Penning, T. M., Dinkova-Kostova, A. T., & Hayes, J. D. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.06.021 · Cited by 837 · cited 1×
“…element in the promoter region of Nrf-2, targeting antioxidant and anti-apoptotic genes, including heme-oxygenase 1 (HO-1) (Pan et al., 2013; Tebay et al., 2015), which catalyzes heme degradation and the production of carbon monoxide (CO), ferrous iron (Fe2+), and biliverdin (Kim et al.,…”
BackgroundHeddleston, J. M., Li, Z., McLendon, R. E., Hjelmeland, A. B., & Rich, J. N. (2009) · Cell Cycle · doi:10.4161/cc.8.20.9701 · Cited by 813
Cancer cell killing via ROS: To increase or decrease, that is the question
Wang, J., & Yi, J. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.12.7067 · Cited by 790 · cited 1×
“The second hypothesis suggests that when both tumor and normal cells are subjected to comparable levels of exogenous ROS-producing agents, the intracellular ROS levels of tumor cells increase more readily than normal cells to attain a threshold and induce cell death (Wang and Yi, 2008).”
BackgroundPham, C. G., Bubici, C., Zazzeroni, F., Papa, S., Jones, J., Alvarez, K., Jayawardena, S., De Smaele, E., Cong, R., Beaumont, C., et al. (2004) · Cell · doi:10.1016/j.cell.2004.10.017 · Cited by 663
Mitochondrial complex III regulates hypoxic activation of HIF
Klimova, T., & Chandel, N. S. (2008) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402307 · Cited by 433 · cited 1×
“The production of ROS in mild hypoxic environments could be the result of deregulation of mitochondrial respiration (Klimova and Chandel, 2008).”
BackgroundManganese superoxide dismutase regulation and cancer
Dhar, S. K., & St. Clair, D. K. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.03.009 · Cited by 196
Sullivan, R., Maresh, G., Zhang, X., Salomon, C., Hooper, J., Margolin, D., & Li, L. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00194 · Cited by 112 · cited 1×
“Recently, EVs have received a significant interest as transporters of biological mediators and have shown to be an important messenger in the intercellular communication between the tumor and the TME (Sullivan et al., 2017).”
BackgroundZhang, Z., Xu, J., Chen, Z., Wang, H., Xue, H., Yang, C., Guo, Q., Qi, Y., Guo, X., Qian, M., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0759 · Cited by 93 · cited 2×
“All these factors have an effect on the metabolism of cells and therefore, on the function of the cells, thus the TME is constantly fluctuating and plays a critical role in drug resistance, angiogenesis, cell death, DNA repair, OS, immune escape, the level and activity of multidrug resistance (MDR)-related genes, tumo…”
BackgroundVaupel, P., & Multhoff, G. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01887 · Cited by 81 · cited 4×
“Tumorigenesis leads to alterations in metabolism, resulting in an amplification in glycolysis, caused by aerobic glycolysis or the “Warburg effect,” which triggers a prompt supply of energy that is correlated to an increased conversion of glucose to lactate (Gatenby and Gillies, 2004; Vander Heiden et al., 2009; Vaupe…”
BackgroundInfluentialSTIM-Orai Channels and Reactive Oxygen Species in the Tumor Microenvironment
Frisch, J., Angenendt, A., Hoth, M., Prates Roma, L., & Lis, A. (2019) · Cancers · doi:10.3390/cancers11040457 · Cited by 68 · cited 1×
“1 to 3%), acidity and alterations in the composition of the ECM and the accretion of soluble factors including O2, nutrients, ROS, RNS, ATP, Ca2+, H, growth factors, chemokines and cytokines (Frisch et al., 2019).”
Background
Cited by
Koo, J., Shin, Y., Jeon, H., Cheong, J., Cho, S., Park, C., Song, E. C., Ramsey, J. D., Lim, C., & Oh, K. T. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.12.058 · Cited by 23
Metadata
- Authors
- Olivier, C., Oliver, L., Lalier, L., & Vallette, F. M.
- Venue
- Frontiers in Molecular Biosciences
- Publisher
- Frontiers Media SA
- Published
- 2021-01-27
- Volume
- 7
- Pages
- 620677-620677
- ISSN
- 2296-889X (ISSN-L)
- OpenAlex
- W3123368520
- Cited by
- 182
- References
- 34
- FWCI
- 13.26
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.